PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33852951-4 2021 The binding activity of rhACE2 to Spike protein of SARS-CoV2 was evaluated in S protein-overexpressed HEK293A cells (HEK293A-SP cells) through flow cytometry. rhace2 24-30 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 34-39 34611521-3 2021 Recombinant human ACE2 (rhACE2) functionalized onto the surface of cytomimetic particles binds the receptor binding domain (RBD) of recombinant SARS-CoV-2 spike protein with high affinity and demonstrated a stoichiometric advantage over the use of soluble rhACE2. rhace2 24-30 angiotensin converting enzyme 2 Homo sapiens 18-22 34611521-3 2021 Recombinant human ACE2 (rhACE2) functionalized onto the surface of cytomimetic particles binds the receptor binding domain (RBD) of recombinant SARS-CoV-2 spike protein with high affinity and demonstrated a stoichiometric advantage over the use of soluble rhACE2. rhace2 24-30 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 155-160 33400951-4 2021 This report compares the ability of recombinant human ACE2 (rhACE2) to metabolize Ang III, Ang IV and Ang V, (4-8 pentapeptide) relative to Ang II to form corresponding des-omega-Phe metabolites. rhace2 60-66 angiotensin converting enzyme 2 Homo sapiens 54-58 33732940-5 2021 In addition, all three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin-converting enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein. rhace2 133-139 angiotensin converting enzyme 2 Homo sapiens 100-131 33732940-5 2021 In addition, all three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin-converting enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein. rhace2 170-176 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 193-198 32264791-9 2020 rhACE2 (recombinant human ACE2) has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively. rhace2 0-6 angiotensinogen Homo sapiens 106-120 33368659-8 2021 Incubation with rhACE2 decreased traditional APs while increasing beneficial alternative APs, and Ang1-7 was significantly higher in the ARB + rhACE2 (880 pg/mL; 95% CI = 560-1383 pg/mL) vs ACEI + rhACE2 (455 pg/mL; 95% CI = 188-1104 pg/mL; P = .03) group. rhace2 143-149 angiopoietin 1 Canis lupus familiaris 98-104 33368659-8 2021 Incubation with rhACE2 decreased traditional APs while increasing beneficial alternative APs, and Ang1-7 was significantly higher in the ARB + rhACE2 (880 pg/mL; 95% CI = 560-1383 pg/mL) vs ACEI + rhACE2 (455 pg/mL; 95% CI = 188-1104 pg/mL; P = .03) group. rhace2 143-149 angiopoietin 1 Canis lupus familiaris 98-104 32864572-7 2020 We presume that restoration of normal functioning of renin-angiotensin system with recombinant human angiotensin-converting enzyme 2 (rhACE2), angiotensin (1-7) and angiotensin (1-9) may be an effective therapeutic measure but studies will be required to test this hypothesis and explore its possible role in treatment of COVID-19. rhace2 134-140 angiotensin converting enzyme 2 Homo sapiens 101-132 33135833-2 2021 HYPOTHESIS/OBJECTIVES: Angiotensin receptor blockers (ARBs) would alter balance of APs and differences would be magnified in vitro by incubation of plasma samples with recombinant human ACE2 (rhACE2). rhace2 192-198 angiotensin converting enzyme 2 Homo sapiens 186-190 32817951-5 2020 In addition, all three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin converting enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein. rhace2 133-139 angiotensin converting enzyme 2 Homo sapiens 100-131 32428864-5 2020 In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine). rhace2 176-182 angiotensin converting enzyme 2 Homo sapiens 61-65 32428864-5 2020 In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine). rhace2 176-182 angiotensin converting enzyme 2 Homo sapiens 146-150 32428864-5 2020 In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine). rhace2 176-182 angiotensin converting enzyme 2 Homo sapiens 146-150 32428864-5 2020 In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine). rhace2 176-182 angiotensin converting enzyme 2 Homo sapiens 146-150 26245758-10 2015 The Ang II-mediated reductions of renal ACE2 and nephrin levels in ApoEKO mice were remarkably rescued by rhACE2 supplementation, along with augmentation of renal Ang-(1-7) levels. rhace2 106-112 angiogenin, ribonuclease, RNase A family, 5 Mus musculus 4-7 26245758-10 2015 The Ang II-mediated reductions of renal ACE2 and nephrin levels in ApoEKO mice were remarkably rescued by rhACE2 supplementation, along with augmentation of renal Ang-(1-7) levels. rhace2 106-112 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 Mus musculus 40-44 26245758-10 2015 The Ang II-mediated reductions of renal ACE2 and nephrin levels in ApoEKO mice were remarkably rescued by rhACE2 supplementation, along with augmentation of renal Ang-(1-7) levels. rhace2 106-112 nephrosis 1, nephrin Mus musculus 49-56 31254308-3 2019 Equilibrium concentrations of renin angiotensin aldosterone system (RAAS) APs differ in dogs with heart disease compared to healthy dogs and recombinant human ACE2 (rhACE2) alters relative concentrations of APs. rhace2 165-171 renin Canis lupus familiaris 30-35 31254308-3 2019 Equilibrium concentrations of renin angiotensin aldosterone system (RAAS) APs differ in dogs with heart disease compared to healthy dogs and recombinant human ACE2 (rhACE2) alters relative concentrations of APs. rhace2 165-171 angiotensin converting enzyme 2 Homo sapiens 159-163